Coronavirus Disease COVID 19 News and Research

Latest Coronavirus Disease COVID 19 News and Research

Is nirmatrelvir treatment of SARS-CoV-2 associated with a lower risk of post–COVID-19 condition?

Researchers performed an observational cohort study using the US Department of Veterans Affairs healthcare databases.

27 Mar 2023

Study finds persistent decrease in daily step count among U.S. adults post-pandemic

In a recent study published in JAMA Network Open, researchers in Tennessee investigated whether the coronavirus disease 2019 (COVID-19) pandemic altered daily step counts among individuals participating in All of Us (AOU) research programs.

27 Mar 2023

The vital role of patients and the general public in guiding long-COVID research

In a recent study published in the journal Nature Medicine, researchers in the United Kingdom (UK) emphasized the significance of public and patient involvement (PPI) in scientific studies on long coronavirus disease (COVID).

27 Mar 2023

A randomized trial of a blood thinner after severe COVID-19 to prevent clotting events

In a recent prospective study published in the Annals of Internal Medicine Journal, researchers in the United States (US) and Spain performed a randomized controlled trial (RCT) across 127 US hospitals between 2021 and 2022.

27 Mar 2023

Curcumin reduces inflammatory responses in post-COVID vaccinated adults

A new study published in the Nutrients Journal highlights the impact of curcumin supplementation on the immune response following the immunization of Coronavirus disease 2019 (COVID-19) survivors with a primary series of monovalent COVID-19 vaccines.

26 Mar 2023

Incidence of tuberculosis reaches 2.5 cases per 100,00 in the U.S.

The United States (US) Centers for Disease Control and Prevention (CDC) has recently released preliminary data on tuberculosis incidence in the US in 2022. The report is published in the Morbidity and Mortality Weekly Report.

26 Mar 2023

Nasally administered molecule effective in preventing all SARS-CoV-2 variants

Researchers have developed a molecule that is, when administered nasally, extremely effective in preventing the disease caused by all known variants of the SARS-CoV-2 virus.

24 Mar 2023

Candida auris infection without epidemiologic links to a prior outbreak

The Centers for Disease Control and Prevention (CDC) has classified Candida auris (C. auris) as an urgent public threat due to its role in elevating mortality, its ability to persist in hospital environments, and the high possibility of developing pan-drug resistance.

23 Mar 2023

U.S. maternal mortality rates rose during COVID-19 pandemic

A new study examines mortality related to pregnancy during the COVID-19 pandemic as compared pre-pandemic rates.

23 Mar 2023

Exploring the complexities of antimicrobial resistance forecasting

Researchers highlight the need for prioritizing research on antimicrobial-resistant organism forecasting.

23 Mar 2023

The policy, and politics, of Medicare Advantage

Medicare Advantage, the private-sector alternative to original Medicare, now enrolls nearly half of all Medicare beneficiaries.

23 Mar 2023

Ingenza celebrates 20 years of innovation

Edinburgh-based Ingenza, a pioneer in engineering biology, is delighted to celebrate its 20th anniversary this month.

From Ingenza Ltd 23 Mar 2023

The effects of COVID-19 on stress, depression, and anxiety in pregnant and postpartum women

A recent study published in the journal Midwifery evaluated depression, stress, and anxiety in pregnant and postpartum individuals during the coronavirus disease 2019 (COVID-19) pandemic.

23 Mar 2023

Reinfections with Omicron VOCs occur more frequently and over shorter intervals

In a recent study published in Nature's Communications Biology journal, researchers in the United States of America (USA) employed next-generation sequencing (NGS) data to assess the rise in reinfections with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant.

23 Mar 2023

Monovalent vs. bivalent vaccines – Which is more effective against SARS-CoV-2?

In a recent study posted to the medRxiv* preprint server, researchers in France compared the efficacy of Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to messenger ribonucleic acid (mRNA) Original (ancestral) monovalent vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

22 Mar 2023

Zoonotic agent Erysipelothrix rhusiopathiae caused mass mortality of harbor porpoises

In a recent article published in the Emerging Infectious Diseases Journal, researchers in the Netherlands described a mortality event that killed hundreds of harbor porpoises (Phocoena phocoena), a small cetacean, along the Netherlands coastline, in August 2021.

22 Mar 2023

Dampened mucosal response against SARS-CoV-2 in pregnant individuals

In a recent study posted to the medRxiv* preprint server, researchers examined associations between coronavirus disease 2019 (COVID-19) outcomes and mucosal antibody responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and viral RNA levels in pregnant individuals.

22 Mar 2023

SARS-CoV-2 infection damages CD8+ T cell response

In a recent study published in the journal Immunity, a team of researchers from the United States found that previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections reduce the activation and expansion of CD8+ T cells in response to coronavirus disease 2019 (COVID-19) vaccinations.

22 Mar 2023

COVID-19 pandemic left high school students sleep-deprived and struggling with mental health

In a recent study published in the Preventing Chronic Disease journal, U.S. Centers for Disease Control and Prevention (CDC) researchers assessed the impact of the coronavirus disease 2019 (COVID-19) pandemic on sleep duration and mental health of high school students.

22 Mar 2023

Higher Paxlovid uptake in winter 2022 could have prevented nearly 5,000 deaths

In a recent study published in the JAMA Health Forum, researchers in the United States estimated the reduction in coronavirus disease 2019 (COVID-19) mortality rates after the Paxlovid rollout.

22 Mar 2023